Pure red cell aplasia evolving through the hyperfibrotic myelodysplastic syndrome to the acute myeloid leukemia: some pathogenetic aspects

Hematology and Cell Therapy ◽

10.1007/s00282-999-0027-5 ◽

1999 ◽

Vol 41 (1) ◽

pp. 27-29 ◽

Author(s):

N. Suvajdzic ◽

D. Marisavljevic ◽

V. Jovanovic ◽

M. Pantic ◽

D. Sefer ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Pure Red Cell Aplasia ◽

Red Cell ◽

Red Cell Aplasia ◽

Download Full-text

Pure Red Cell Aplasia Type III: Progression to Acute Myeloid Leukemia and Absence of the IgG Inhibitor to Erythropoiesis

Preleukemia ◽

10.1007/978-3-642-67470-9_3 ◽

1979 ◽

pp. 12-13

Author(s):

C. Peschle

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Pure Red Cell Aplasia ◽

Red Cell ◽

Type Iii ◽

Red Cell Aplasia ◽

Download Full-text

More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels

Leukemia & Lymphoma ◽

10.1080/10428194.2021.1999446 ◽

2021 ◽

pp. 1-4

Author(s):

Anna B. Halpern ◽

Elihu H. Estey

Keyword(s):

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Hemoglobin Level ◽

Response Criteria ◽

Red Cell ◽

Red Cell Transfusion ◽

Download Full-text

Decision letter for "The Incidence, Risk Factors and Survival of Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome: A Population‐Based Study"

10.1002/hon.2660/v3/decision1 ◽

2019 ◽

Keyword(s):

Risk Factors ◽

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Population Based ◽

Population Based Study ◽

Incidence Risk ◽

Download Full-text

Author response for "The Incidence, Risk Factors and Survival of Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome: A Population‐Based Study"

10.1002/hon.2660/v2/response1 ◽

2019 ◽

Author(s):

Xingnong Ye ◽

Dan Chen ◽

Yan Zheng ◽

Cai Wu ◽

Xiaoqiong Zhu ◽

...

Keyword(s):

Risk Factors ◽

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Population Based ◽

Author Response ◽

Population Based Study ◽

Incidence Risk ◽

Download Full-text

Decision letter for "The Incidence, Risk Factors and Survival of Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome: A Population‐Based Study"

10.1002/hon.2660/v2/decision1 ◽

2019 ◽

Keyword(s):

Risk Factors ◽

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Population Based ◽

Population Based Study ◽

Incidence Risk ◽

Download Full-text

Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome

10.32388/p7v2fx ◽

2020 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Alkylating Agent ◽

Download Full-text

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Case Medical Research ◽

10.31525/ct1-nct03940352 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Download Full-text

Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Case Medical Research ◽

10.31525/ct1-nct03969446 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Newly Diagnosed ◽

Download Full-text

Faculty Opinions recommendation of Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.10197.467594 ◽

2006 ◽

Author(s):

Mayumi Mori

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Prognostic Models ◽

Intensive Chemotherapy ◽

Download Full-text

Faculty Opinions recommendation of A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119427.575617 ◽

2008 ◽

Author(s):

Arati Rao

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Low Dose ◽

Randomized Study ◽

Line Therapy ◽

Low Dose Cytarabine ◽

Download Full-text